Netta Mäkinen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7231005/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	<i>MED12</i> , the <i>Mediator Complex Subunit 12</i> Gene, Is Mutated at High Frequency in Uterine Leiomyomas. Science, 2011, 334, 252-255.	12.6	547
2	Characterization of Uterine Leiomyomas by Whole-Genome Sequencing. New England Journal of Medicine, 2013, 369, 43-53.	27.0	280
3	Integrated data analysis reveals uterine leiomyoma subtypes with distinct driver pathways and biomarkers. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 1315-1320.	7.1	166
4	Genomics of uterine leiomyomas:Âinsights from high-throughput sequencing. Fertility and Sterility, 2014, 102, 621-629.	1.0	164
5	Uterine Leiomyoma-Linked MED12 Mutations Disrupt Mediator-Associated CDK Activity. Cell Reports, 2014, 7, 654-660.	6.4	125
6	MED12 exon 2 mutations are common in uterine leiomyomas from South African patients. Oncotarget, 2011, 2, 966-969.	1.8	95
7	Exome Sequencing of Uterine Leiomyosarcomas Identifies Frequent Mutations in TP53, ATRX, and MED12. PLoS Genetics, 2016, 12, e1005850.	3.5	94
8	Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors. Molecular Cancer, 2017, 16, 101.	19.2	74
9	MED12 exon 2 mutations in histopathological uterine leiomyoma variants. European Journal of Human Genetics, 2013, 21, 1300-1303.	2.8	66
10	MED12 mutation frequency in unselected sporadic uterine leiomyomas. Fertility and Sterility, 2014, 102, 1137-1142.	1.0	62
11	Exome-wide somatic mutation characterization of small bowel adenocarcinoma. PLoS Genetics, 2018, 14, e1007200.	3.5	62
12	Deficient H2A.Z deposition is associated with genesis of uterine leiomyoma. Nature, 2021, 596, 398-403.	27.8	53
13	MED12 mutations and FH inactivation are mutually exclusive in uterine leiomyomas. British Journal of Cancer, 2016, 114, 1405-1411.	6.4	43
14	Exomic landscape of <i>MED12</i> mutationâ€negative and â€positive uterine leiomyomas. International Journal of Cancer, 2014, 134, 1008-1012.	5.1	36
15	Somatic <i>MED12</i> mutations in prostate cancer and uterine leiomyomas promote tumorigenesis through distinct mechanisms. Prostate, 2016, 76, 22-31.	2.3	33
16	Global metabolomic profiling of uterine leiomyomas. British Journal of Cancer, 2017, 117, 1855-1864.	6.4	29
17	Somatic <i>MED12</i> Nonsense Mutation Escapes mRNA Decay and Reveals a Motif Required for Nuclear Entry. Human Mutation, 2017, 38, 269-274.	2.5	20
18	Clonally related uterine leiomyomas are common and display branched tumor evolution. Human Molecular Genetics, 2015, 24, 4407-4416.	2.9	19

2

Netta MÃ**r**inen

#	Article	IF	CITATIONS
19	Patterns of chromosome 18 loss of heterozygosity in multifocal ileal neuroendocrine tumors. Genes Chromosomes and Cancer, 2020, 59, 535-539.	2.8	16
20	Comparison of 2SC, AKR1B10, and FH Antibodies as Potential Biomarkers for FH-deficient Uterine Leiomyomas. American Journal of Surgical Pathology, 2022, 46, 537-546.	3.7	8
21	Parity associates with chromosomal damage in uterine leiomyomas. Nature Communications, 2021, 12, 5448.	12.8	2
22	Genomic Evolution in a Patient With Lung Adenocarcinoma With a Germline EGFR T790M Mutation. JTO Clinical and Research Reports, 2021, 2, 100146.	1.1	0